News + Resources
New BIO & TEConomy Report and the Importance of Life Sciences M&A
A recent report from BIO and TEConomy notes that decades of growth in the life sciences have been “rooted in, and enabled by, basic and applied research and development activities; development of, and access to, a qualified and highly skilled workforce; [and]...
Innovations Advanced by M&A: A Breakthrough Precision Therapy for Rare Cancers
In the case of Ignyta’s acquisition by Roche, M&A played a pivotal role in accelerating a new precision therapy to patients battling rare forms of cancer.
Founded in 2011 by Drs. David Lim and Gary Firestein, Ignyta initially focused on developing diagnostics for rheumatoid arthritis. However, after facing early scientific setbacks, the company pivoted its focus to advancing entrectinib, a promising investigational therapy for certain types of cancer caused by rare genetic mutations, along with developing diagnostic tests to help identify these mutations.
Preserving Michigan’s Competitive Bioscience Industry
For over 150 years, Michigan has been at the forefront of bringing biopharmaceutical advances to patients across the country and around the world. This is not simply a byproduct of economic luck or chance, but rather the culmination of competitive mergers and...
Forbes Commentary: Trump Administration Should Reverse “Anti-Merger” Approach to M&A
The culmination of flawed antitrust policies by the Federal Trade Commission (FTC) and Department of Justice (DOJ) have discouraged pro-competitive mergers that could meaningfully benefit American consumers – a growing concern raised by former FTC general counsel and...
Innovations Advanced by M&A: New Treatment Options for Migraines
For many small and early-stage life science companies, making the leap from research and development (R&D) to manufacturing and distribution of a new treatment can be an insurmountable barrier. Pfizer’s acquisition of Biohaven Pharmaceuticals, for example, accelerated the global distribution of two new migraine therapies, while also allowing the early-stage company to continue pursuing new scientific breakthroughs.